BR112023017808A2 - Terapia genética de hb-egf para diabetes - Google Patents

Terapia genética de hb-egf para diabetes

Info

Publication number
BR112023017808A2
BR112023017808A2 BR112023017808A BR112023017808A BR112023017808A2 BR 112023017808 A2 BR112023017808 A2 BR 112023017808A2 BR 112023017808 A BR112023017808 A BR 112023017808A BR 112023017808 A BR112023017808 A BR 112023017808A BR 112023017808 A2 BR112023017808 A2 BR 112023017808A2
Authority
BR
Brazil
Prior art keywords
diabetes
growth factor
gene therapy
relates
present
Prior art date
Application number
BR112023017808A
Other languages
English (en)
Portuguese (pt)
Inventor
Eriko Matsuda
Ken-Ichiro Kosai
Original Assignee
Univ Kagoshima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kagoshima filed Critical Univ Kagoshima
Publication of BR112023017808A2 publication Critical patent/BR112023017808A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023017808A 2021-03-03 2022-03-02 Terapia genética de hb-egf para diabetes BR112023017808A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021033714 2021-03-03
JP2021145796 2021-09-07
PCT/JP2022/008898 WO2022186282A1 (ja) 2021-03-03 2022-03-02 糖尿病に対するhb-egf遺伝子治療

Publications (1)

Publication Number Publication Date
BR112023017808A2 true BR112023017808A2 (pt) 2023-09-26

Family

ID=83154306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017808A BR112023017808A2 (pt) 2021-03-03 2022-03-02 Terapia genética de hb-egf para diabetes

Country Status (12)

Country Link
US (1) US20240173381A1 (cg-RX-API-DMAC7.html)
EP (1) EP4302785A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022186282A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240004273A (cg-RX-API-DMAC7.html)
AU (1) AU2022230492A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023017808A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212726A1 (cg-RX-API-DMAC7.html)
IL (1) IL305627A (cg-RX-API-DMAC7.html)
MX (1) MX2023010315A (cg-RX-API-DMAC7.html)
PH (1) PH12023552425A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022186282A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309227B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
JP7868817B2 (ja) * 2024-04-02 2026-06-02 国立大学法人 鹿児島大学 糖尿病に対するsHB-EGF強化治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4839476B2 (ja) * 2005-09-28 2011-12-21 国立大学法人 鹿児島大学 ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途
JP2007223939A (ja) * 2006-02-22 2007-09-06 Kobe Univ エネルギー代謝促進因子としてのhb−egfの使用
JP5174022B2 (ja) * 2007-07-20 2013-04-03 学校法人 埼玉医科大学 膵臓β細胞増加促進剤及び膵臓β細胞増加促進組成物
JP6711495B1 (ja) 2019-05-27 2020-06-17 株式会社ナイスリー 車両用盗難防止装置
JP2021033714A (ja) 2019-08-26 2021-03-01 東芝テック株式会社 商品販売データ処理装置及びプログラム
JP7040807B2 (ja) 2020-03-17 2022-03-23 株式会社オリンピア 遊技機

Also Published As

Publication number Publication date
WO2022186282A1 (ja) 2022-09-09
MX2023010315A (es) 2023-11-24
ZA202309227B (en) 2024-06-26
PH12023552425A1 (en) 2024-02-19
CA3212726A1 (en) 2022-09-09
US20240173381A1 (en) 2024-05-30
AU2022230492A1 (en) 2023-10-19
JPWO2022186282A1 (cg-RX-API-DMAC7.html) 2022-09-09
IL305627A (en) 2023-11-01
EP4302785A1 (en) 2024-01-10
KR20240004273A (ko) 2024-01-11
EP4302785A4 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
Moriondo et al. Proteoglycan fragmentation and respiratory mechanics in mechanically ventilated healthy rats
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
Mang et al. Awake extracorporeal membrane oxygenation for COVID-19–induced acute respiratory distress syndrome
Luo et al. The role of brain barriers in the neurokinetics and pharmacodynamics of lithium
MX2023010315A (es) Terapia génica con factor de crecimiento tipo factor de crecimiento epidérmico de unión a la heparina (hb-egf) para la diabetes.
BR112018006480A2 (pt) ?vetor, método de tratamento de uma doença ou condição, composição, combinação de um vetor, kit, uso de um vetor, método para a modulação in vivo da atividade eletrofisiológica de uma célula
Zaballos et al. Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial
Sharma et al. Endotracheal intubation through the intubating laryngeal mask airway (LMA-Fastrach™): A randomized study of LMA-Fastrach™ wire-reinforced silicone endotracheal tube versus conventional polyvinyl chloride tracheal tube
Lan et al. Influence of lateral position and pneumoperitoneum on oropharyngeal leak pressure with two types of laryngeal mask airways
Hadaczek et al. Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain
WO2022177742A3 (en) Tirzepatide therapeutic methods
Amos et al. Survival following traumatic thoracic compartment syndrome managed with VV-ECMO
Cho et al. Anesthetic management of a patient with glucose-6-phosphate dehydrogenase deficiency undergoing robot-assisted laparoscopic surgery-A case report
McCormack et al. Reply to ‘Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) in children: a randomized controlled trial’
Göktaş et al. Dexmedetomidine and fentanyl in endotracheal intubation: a comparative analysis of hemodynamic and intubation responses
Perilli et al. Carbon dioxide absorption during retroperitoneoscopic adrenalectomy: comparison between monolateral and synchronous bilateral approaches
Cao High-flow nasal cannula versus nasal cannula for advanced bronchoscopy
Mishra Comparative Hemodynamic Efficacy of Intubating LMA Fastrach and Ambu Aura–I as a Conduit for Intubation during General Anaesthesia In Adult: A Randomized, Clinical Study
Sayed El Hefny et al. Effect of stepwise lung recruitment maneuver on oxygenation, lung mechanics and lung injury biomarkers during lung resection surgery: a prospective randomized controlled single blinded study
Xue-mei et al. Clinical application of noninvasive positive pressure ventilation in patients with chronic obstructive pulmonary disease and analysis of the failure risk factors
Sommariva et al. Treatment of acute iatrogenic cystitis secondary to bladder chemo-immuno-instillation or pelvic radiotherapy
LONG et al. Effect of general anesthesia under guidance of bispectral index on postoperative fatigue syndrome in elderly patients undergoing laparoscopic resection of gastrointestinal tumor
BOZDOĞAN et al. Reversal of Rocuronium Induced Bronchospasm Via Injection of Sugammadex
Phoophiboon et al. Successful prone positioning after recent caesarean section in severe ARDS with postpartum pulmonary haemorrhage
Raja Milrinone for pulmonary hypertension: Additional benefits, concerns, and caution